Fundamental Short Selling Research

Eric Fernandez, CFA

TwoRiversAnalytics

Equity Bottom-Up

<ul>
<li>This model looks for slowing growth, margin declines, sales and/or earnings disappointments, troubling working capital trends, poor estimate trends or lowered guidance, among other characteristics.</li>
<li>The key judgement is whether a slowdown is temporary or the beginning of a trend.  These shorts tend to have high valuations and betas.  Multiple compression accelerates the stock’s decline.</li>
<li>Today we are flagging Quanterix, Insulet, Inari Med,  and MercadoLibre</li>
</ul>


This model looks for slowing growth, margin declines, sales and/or earnings disappointments, troubling working capital trends, poor estimate trends or lowered guidance, among other characteristics.
The key judgement is whether a slowdown is temporary or the beginning of a trend.  These shorts tend to have high valuations and betas.  Multiple compression accelerates the stock’s decline.
Today we are flagging Quanterix, Insulet, Inari Med,  and MercadoLibre


Breaking Growth Short Candidates: Quanterix, Insulet, Inari Med, MercadoLibre

Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

Algosun Global

<p><a href="https://www.smartkarma.com/entities/inari-medical-inc" target="_blank" data-smartkarma-citation="entities:34650:1" rel="noopener">Inari Medical (NARI US)</a> , American high-growth venous company went public in 2020. Medical device firm priced IPO at $19.00 per share, sold ~8.2 million shares and raised net proceeds of more than $150 million. Inari Medical stock significantly outperformed when compared to peers and rose 300%+ since IPO. We believe Inari Medical can continue its growth trajectory over the next 3-4 years keeping in mind relocating into 120K sq. ft. facility in Irvine, California, what allows to more than double manufacturing capacity. Moreover, the company has already completed ClotTriever and FlowTriever cases across major countries in Western Europe and plans to expand into APAC region – China and Japan, in the foreseeable future.     </p>

Inari Medical (NARI US) , American high-growth venous company went public in 2020. Medical device firm priced IPO at $19.00 per share, sold ~8.2 million shares and raised net proceeds of more than $150 million. Inari Medical stock significantly outperformed when compared to peers and rose 300%+ since IPO. We believe Inari Medical can continue its growth trajectory over the next 3-4 years keeping in mind relocating into 120K sq. ft. facility in Irvine, California, what allows to more than double manufacturing capacity. Moreover, the company has already completed ClotTriever and FlowTriever cases across major countries in Western Europe and plans to expand into APAC region – China and Japan, in the foreseeable future.     

Inari Medical: Innovative Devices For the Treatment of Venous Diseases

United States

Inari Medical, Inc.manufactures medical device. The Company offers catheter-based technologies for the treatment of venous thromboembolism. Inari Medical serves customers in the State of California.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Inari Medical (NARI US)

Breaking Growth Short Candidates: Quanterix, Insulet, Inari Med, MercadoLibre

Breaking Growth stocks combine declining fundamentals with multiple compression. This week we flag: Quanterix, Insulet, Inari Med, MercadoLibre

Eric Fernandez, CFA

Inari Medical: Innovative Devices For the Treatment of Venous Diseases

Inari Medical is well positioned to gain share in a $4B+ market and there is ample room for growth for market leader targeting venous diseases

Andrei Zakharov

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)